Symposium
Plenary Hall: Lomond Auditorium
Plenary Hall: Lomond Auditorium
Saturday, June 27, 05:40 PM – 06:55 PM
Symposium 8:
Implementation of Pharmacogenetics in Psychiatry across the World
Implementation of Pharmacogenetics in Psychiatry across the World
Individualizing treatment with established medications is one possible approach to significantly reduce the burden and health care costs per patient. Today, only about one third of patients attending psychiatric facilities respond fully to treatment with the available arsenal of medications.
Pharmacogenetic testing can improve medication selection and dosing by identifying individual-specific genetic variants that affect drug-metabolizing enzymes, drug transporters or drug targets. In addition, genotype-dependent dosing guidelines for psychotropic drugs are available to physicians4.
Whereas an abundance of commercially available tests may suggest that pharmacogenetic approaches are a well-established tool in psychiatry, backed by a host of robust studies, this is not the case. The global psychiatric community still lacks an awareness and thorough understanding of the subject.
Despite the immense potential of pharmacogenetic approaches, most countries have yet to incorporate them into routine clinical practices. Progress has been hindered by unwarranted optimism and overstated claims. In this first session of the newly formed CINP Pharmacogenetics Global Networking Community an overview of implementation across the world will be provided.
Pharmacogenetic testing can improve medication selection and dosing by identifying individual-specific genetic variants that affect drug-metabolizing enzymes, drug transporters or drug targets. In addition, genotype-dependent dosing guidelines for psychotropic drugs are available to physicians4.
Whereas an abundance of commercially available tests may suggest that pharmacogenetic approaches are a well-established tool in psychiatry, backed by a host of robust studies, this is not the case. The global psychiatric community still lacks an awareness and thorough understanding of the subject.
Despite the immense potential of pharmacogenetic approaches, most countries have yet to incorporate them into routine clinical practices. Progress has been hindered by unwarranted optimism and overstated claims. In this first session of the newly formed CINP Pharmacogenetics Global Networking Community an overview of implementation across the world will be provided.
05:40 PM – 06:05 PM
25 min
25 min